… In this study, stable CAD was characterized by patients who had either undergone … to our
findings, having platelet stimulated with a more potent agonist or a combination of two agonists …

… Coronary artery bypass grafting (CABG) is the most effective treatment for multivessel … and
progression of CAD (4, 5). When performing surgical revascularization, potent inflammatory …

… by-pass graft (CABG) techniques and more potent antiplatelet … independent risk factor for
the development of CAD. Coronary … Recent data on diabetic patients undergoing PCI revealed …

… potent antiischemic and antiarrhythmic protection in patients … observed in patients with
coronary artery disease and often … Our small experience includes 37 patients treated according …

… bypass grafting (CABG) in multi-vessel coronary artery disease (… stents (DES) and more
potent antiplatelet agents, in addition … The aim of this editorial is to discuss factors influencing the …

… of patients undergoing coronary artery bypass graft (CABG) … age to be the cause of their
coronary heart disease (CHD) and … “ Laypersons” representations of illness can have a potent …

… We recruited CAD patients who were aged over 18 years … for graft occlusion, MI, or death
in patients post‐CABG. Apart … on mRNA stability, but is potent in inhibiting protein translation. …

… in patients with significant CAD undergoing CABG or PCI 4-17… the treatment of left main CAD,
PCI compared with CABG had … In general, potent antiplatelet therapy significantly increases …

… treatment of coronary artery disease (CAD). Saphenous vein … Production of nitric oxide
(NO), prostacyclin, and potent … are not applicable to all patients who underwent CABG. Finally, …

… bypass grafting (CABG) is associated with long-term survival benefit in patients with multivessel
coronary artery disease (CAD… CABG was theorized as an “infarct-reducing treatment” [2], …